迷走神経刺激市場

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) Global Health Observatory, National Institute of Neurological Disorders and Stroke (NINDS), American Academy of Neurology (AAN), American Epilepsy Society (AES), European Academy of Neurology (EAN), International League Against Epilepsy (ILAE), American Association of Neurological Surgeons (AANS), Congress of Neurological Surgeons (CNS), National Center for Health Statistics (NCHS), EU Eurostat Health Database, Health Canada, Therapeutic Goods Administration (TGA) Australia, Pharmaceuticals and Medical Devices Agency (PMDA) Japan, and national health ministry reports from key markets. These sources were used to collect epilepsy and neurological disorder prevalence statistics, regulatory approval data for VNS devices, clinical safety and efficacy studies, demographic trends, reimbursement policies, and neuromodulation market landscape analysis for implantable VNS systems, external VNS devices, transcutaneous VNS technologies, and non-invasive neuromodulation therapies.

In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, heads of regulatory affairs, R&D directors, and commercial directors from makers of vagal nerve stimulation devices, neuromodulation firms, and medical device OEMs were examples of supply-side sources. Board-certified neurologists, epileptologists, neurosurgeons, psychiatrists, pain management specialists, medical directors of epilepsy centers, procurement leads from hospitals and academic medical centers, administrators from ambulatory surgical centers, and experts in healthcare technology assessment were among the demand-side sources. Primary research verified product pipeline timelines for next-generation VNS devices, validated market segmentation across indication categories (epilepsy, depression, chronic pain, migraine, heart failure), and obtained information on clinical adoption patterns, pricing strategies, reimbursement dynamics, and competitive positioning between invasive and non-invasive technologies.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)

By Region: North America (38%), Europe (25%), Asia-Pacific (28%), Rest of World (9%)

Global market valuation was derived through revenue mapping, procedure volume analysis, and device installation base tracking. The methodology included:

Identification of 35+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in neuromodulation and VNS technologies

Product mapping across implantable VNS devices, external VNS systems, transcutaneous VNS devices, and wearable neuromodulation technologies

Analysis of reported and modeled annual revenues specific to vagal nerve stimulation portfolios, including device sales, implantation procedures, and recurring revenue from battery replacements and lead revisions

Coverage of manufacturers representing 75-80% of global market share in 2024, including Medtronic, LivaNova, Boston Scientific, Abbott Laboratories, NeuroPace, ElectroCore, and emerging players in non-invasive VNS

Extrapolation using bottom-up (procedure volume × ASP by country/region, implantation rates per 100,000 epilepsy population, replacement cycle analysis) and top-down (manufacturer revenue validation, neuromodulation market allocation) approaches to derive segment-specific valuations across indication, device type, end user, technology, and patient type categories